We read with great interest the study by Zeitler et al of patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) trial, in
which the authors demonstrated that, in patients with left bundle branch block, the relative benefit of CRT in addition to the implantable cardioverter-defibrillator (ICD) did not significantly change according to the burden of comorbidity (1) . To the best of our knowledge, this was the first large study demonstrating that CRT may be beneficial regardless of the number of comorbidities.
To which extent those findings, from a randomized controlled trial, are replicable in a "real life" setting remains to be determined. To the best of our knowledge, there are no data available in the literature. We took the opportunity to test this hypothesis in a large French registry of primary prevention ICDs and CRT-Ds (Défibrillateur Automatique Implantable Prévention Primaire -DAI-PP) through the analysis of 3,573 patients with prolonged QRS (>120 ms) (2, 3). We assessed the association of multiple comorbidities (coronary artery disease, atrial fibrillation, cerebrovascular disease, respiratory disease, renal dysfunction and previous malignancy) with the benefits of CRT-D (n=2459) compared with single-or dual-chamber ICD alone (n=1114). As expected, unadjusted overall mortality increased with increasing comorbidity burden (41.2 deaths per 1000 patient-years in patients with 0-1 comorbidities, vs. 48.3 and 70 per 1000 patient-years in those with 2 or ≥3 comorbidities, respectively, p<0.001), with non-cardiovascular death accounting for much of the difference between comorbidity groups. Likewise, the probability of CRT response decreased with increasing number of comorbidities, but even those with multiple comorbidities had a good probability of responding (82.6% in patients with 0-1 comorbidities, compared with 77% in 1560 patients with 2 comorbidities and 71.1% in individuals with ≥3 comorbid conditions (p<0.001).
Proportional hazards regression with adjustment on the propensity score and mortality predictors was In summary, our real world data support the findings of Zeitler et al (1) . As expected, there were differences in the risk of death and probability of CRT response among comorbidity groups but, as seen in the long-term follow-up of MADIT-CRT, the burden of comorbidity did not appear to significantly influence the probability of response to CRT, despite a potentially smaller survival benefit in patients with ≥3 comorbidities. Although ICD implantation should be carefully considered in patients with multiple comorbidities, CRT should not be withhold in this context of heart failure patient with enlarged QRS. 
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